Nonetheless, over half of this cohort found AA to be moderately or seriously financially burdensome, and the average out-of-pocket costs of $1354 is similar to the average out-ofpocket costs of $1418 for patients with psoriasis. 4 The reallife willingness to pay of this cohort reflects the consequences of AA on the everyday lives of patients. Although future work is required to confirm these results and determine their generalizability to the overall community of patients with AA, these findings suggest that the negative psychological consequences of AA may be compounded by financial distress, which has been shown to place patients at risk for worse quality of life.
life willingness to pay of this cohort reflects the consequences of AA on the everyday lives of patients. Although future work is required to confirm these results and determine their generalizability to the overall community of patients with AA, these findings suggest that the negative psychological consequences of AA may be compounded by financial distress, which has been shown to place patients at risk for worse quality of life. 5 As payers begin to explore coverage around an increasingly promising pipeline for AA treatments, we hope that this evaluation can encourage broader financial coverage for treatments of this psychologically and financially burdensome disease-not just for pharmaceuticals, but for supplementary therapies as well. Physicians should be aware of the potential ramifications of treatment costs for patients and consider financial impairment as an unintended consequence of their recommendations. studies focusing on treatment of skin disease in CADM remain an unmet need.
Methods | To investigate the use of systemic treatment for skin disease in CADM at 4 tertiary care centers, an institutional review board-approved (Brigham and Women's and New York University Hospitals) search of Partners HealthCare (Research Patient Data Registry, encompassing more than 2 billion patient data points) and New York University electronic medical record systems was performed between January 1, 2000, and December 31, 2016. The search was conducted using natural language queries and International Classification of Diseases codes for amyopathic and hypomyopathic DM. A total of 115 patients diagnosed and managed by a board-certified dermatologist or rheumatologist were included. All patients for whom treatment was not specifically prescribed for skin manifestations of CADM were excluded. . Thirteen patients were followed exclusively by a rheumatology provider, and none of these patients received intravenous immunoglobulin compared with 32.4% (33 of 102) of patients followed exclusively by a dermatology provider (P = .02) ( Table 2) . Because existing data support the efficacy of intravenous immunoglobulin for skin disease in DM, this difference in treatment approach may alter patient outcomes.
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Discussion | This study emphasizes the recalcitrant nature of DM skin disease. Antimalarial agents have often been reported as firstline treatment for cutaneous DM. However, in this study, patients rarely responded sufficiently to antimalarial agents, and 30.7% (27 of 88) developed a morbilliform eruption in response to antimalarial therapy, which can subsequently aggravate cutaneous DM. At our institutions, patients with DM who are prescribed hydroxychloroquine are given a pretreatment warning regarding the risk of a drug-related eruption. Furthermore, in patients with moderate or severe skin disease, given the low response rate to antimalarial therapy alone, a more aggressive therapy (eg, methotrexate or mycophenolate mofetil) is typically started as initial therapy alone or in conjunction with hydroxychloroquine. This study highlights that aggressive therapy is often warranted on the basis of cutaneous involvement alone, especially given that CADM is typically a chronic condition that negatively influences quality of life and in which full remission may take years. 2 Although this is the largest reported cohort of patients with CADM to date, our study is limited by small sample size, lack of an available skin severity measure given its retrospective nature, and potential increased disease severity among patients in tertiary care centers. Further studies are warranted to better characterize therapeutic response in CADM.
Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy
Talimogene laherparepvec (TVEC) is a genetically modified, live oncolytic herpes simplex virus 1 therapy containing the granulocyte macrophage colony stimulating factor gene (GM-CSF). Approved by the US Food and Drug Administration in 2015 for treatment of unresectable melanoma in the skin and lymph nodes, this injectable immunotherapy delivers an antitumor effect through improved antigen presentation, T-cell priming, and by direct lysis of tumor cells. 1 Response to therapy is generally assessed clinically through lesion regression. However, assessment may be confounded by pigment retention in the absence of persistent melanoma.
Report of a Case | A 48-year-old man was diagnosed with a nonulcerated, 0.87-mm, Clark level IV superficial spreading melanoma on the scalp with 2 mitoses/mm 2 and lymphovascular invasion. After a wide local excision and skin graft, extensive pigmented plaques and nodules grew within months around the graft site. A positron-emission tomography/computed tomography scan revealed a focus of avidity in the colon, found to be a polyp on colonoscopy. Findings of brain magnetic resonance imaging were negative. The patient began treatment with pembrolizumab for unresectable melanoma, but owing to tumor progression after 3 cycles of therapy, TVEC was added. After 2 TVEC 
